Clinical Trial Detail

NCT ID NCT03336333
Title A Study Comparing BGB-3111 With Bendamustine Plus Rituximab in Patients With Previously Untreated CLL or SLL
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors BeiGene
Indications

CLL/SLL

Therapies

Zanubrutinib

Bendamustine + Rituximab

Age Groups: senior adult

No variant requirements are available.